{"entity":{"id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","aka":[],"tldr":"Two people can have identical treatment and only one develops heart failure or a second cancer years later. Collecting blood and genetic data from survivors could reveal who is at risk and who can be reassured.","summary":"Genetic variants (for instance in anthracycline cardiotoxicity), clonal haematopoiesis, and circulating biomarkers may predict late effects, but studies are small and scattered. A prospective survivor biobank with baseline and serial samples linked to treatment exposures and long-term outcomes would allow discovery and validation of predictive markers, enabling risk-adapted surveillance and preventive therapy.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics","url":"https://cancercontrol.cancer.gov/ocs/statistics"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cardio-oncology","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-biomarker-validation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Within six years the biobank will validate at least one biomarker or polygenic score that stratifies late cardiotoxicity or second-cancer risk with sufficient discrimination to change surveillance intensity.","rationale":"Pharmacogenomic predictors of toxicity have been found where cohorts were large enough; late effects have never had such a resource.","test":"Enrol 20,000 survivors with samples at end of treatment and five years, linked to registry outcomes, with pre-registered discovery and validation analyses.","maturity":"speculative","actor":"research","cost":"medium","horizonYears":6},"route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","neighbours":{"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"rejuv-paed-chronic-disease-burden","kind":"technology","name":"How much illness childhood cancer survivors carry, and at what age","route":"/technologies/rejuv-paed-chronic-disease-burden/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}],"roadmap":[{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/"}]}}